Related Experiment Video

Updated: Jun 10, 2026

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Published on: January 26, 2019

New insights for development of a safe and protective RSV vaccine

Jorge C G Blanco1, Marina S Boukhvalova, Kari Ann Shirey

  • 1Virion Systems Inc., Rockville, MD, USA. jblanco@virionsystmes.com

Human Vaccines
|July 31, 2010
PubMed

Insights

Developing a safe Respiratory Syncytial Virus (RSV) vaccine is critical. Past vaccine trials caused severe illness, highlighting the need to understand immune responses to prevent enhanced disease and ensure long-term protection.

Area of Science:

  • Virology
  • Immunology
  • Vaccinology

Background:

  • Respiratory Syncytial Virus (RSV) is a major cause of severe respiratory illness in infants globally.
  • No licensed RSV vaccine currently exists.
  • A 1960s formalin-inactivated RSV (FI-RSV) vaccine trial resulted in enhanced disease and fatalities upon natural infection.

Purpose of the Study:

  • To review the historical challenges in RSV vaccine development.
  • To explore recent findings on host immune responses to RSV.
  • To identify strategies for creating a safe and effective RSV vaccine.

Main Methods:

  • Literature review of early RSV vaccine trials.
  • Analysis of current research on innate and adaptive immunity to RSV.
  • Synthesis of information to guide future vaccine design.

Main Results:

  • Historical vaccine failures underscore the complexity of inducing protective immunity.
  • Understanding host-pathogen interactions is key to preventing immunopathology.
  • Immune "re-education" is proposed as a strategy for safe RSV vaccination.

Conclusions:

  • Developing a safe and effective RSV vaccine requires a deep understanding of immune responses.
  • Preventing vaccine-enhanced RSV disease is paramount.
  • Future RSV vaccines must elicit appropriate immune responses for long-term protection.

More Related Videos

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses11:48

Generation, Amplification, and Titration of Recombinant Respiratory Syncytial Viruses

Published on: April 4, 2019

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection12:09

Protocol for Recombinant RBD-based SARS Vaccines: Protein Preparation, Animal Vaccination and Neutralization Detection

Published on: May 2, 2011

Related Concept Videos

Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Development of Immunocompetence01:22

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...